Nasopharyngeal carcinoma and the EBV-specific T cell response: prospects for immunotherapy.
T cells specific for Epstein-Barr virus (EBV) can effectively target the virus-transformed B lymphoproliferative lesions that arise in immunosuppressed transplant patients. This review explores the possibility of developing similar T cell-based strategies to treat an EBV-positive epithelial tumour, nasopharyngeal carcinoma (NPC), which arises in relatively immunocompetent individuals and where EBV antigen expression in the tumour is more limited.
Lee
Steven P
SP
Cancer Research UK Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. leesp@divcs-ex1.bham.ac.uk
D000595:Amino Acid Sequence; D017951:Antigen Presentation; D018984:Epitopes, T-Lymphocyte; D019309:Epstein-Barr Virus Nuclear Antigens / Q000032:analysis; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D016219:Immunotherapy, Adoptive; D008969:Molecular Sequence Data; D009303:Nasopharyngeal Neoplasms / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology*
D018984:Epitopes, T-Lymphocyte; D019309:Epstein-Barr Virus Nuclear Antigens; C417029:EBV-encoded nuclear antigen 1